NCT04054050Completed
Bright Light Therapy for Sleep Disturbance in People With Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
Sleep disturbance is common in people with multiple sclerosis (MS) and contributes to diminished quality of life. Bright light therapy may be an innovative strategy to reduce sleep disturbance in MS, possibly through its effects on a subtype of retinal ganglion cells that help regulate circadian rhythms and sleep. This pilot study will evaluate whether, in people with MS, bright light therapy reduces sleep disturbance and explore whether light therapy improves function of these cells.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 27 (actual)
- First submitted
- 9 Aug 2019
- Start date
- 22 Feb 2021
- Primary completion date
- 30 Dec 2025
- Lead sponsor
- Johns Hopkins University
- Diseases
- Multiple sclerosis
- NCT number
- NCT04054050
What you commit to
- Study type: Interventional
- Participants enrolled: 27
- From 22 Feb 2021 to the primary completion date, 30 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- No prior history of bipolar disorder
Other illness
- Evidence of cognitive impairment
- Other comorbid ophthalmologic disorders (e.g. cataracts, glaucoma, blindness)
- MS relapse or history of acute optic neuritis within 30 days
- Diagnosis of severe periodic limb movement disorder or severe restless legs syndrome
Other
- Low risk for sleep disordered breathing
- Traveled across two time zones within 90 days of study screening.
- Not participating in shift work
- No evidence of current depression
Who the study is looking for
- Diagnosis of MS
- Evidence of sleep disturbance
- Stable on immunomodulatory MS therapy or no therapy for at least 6 months prior to study initiation
- Stable on antidepressants for at least 3 months prior to study initiation and no evidence
- Stable on fatigue medication for at least 3 months prior to study initiation
- Willing and able to provide informed consent and follow study procedures.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Johns Hopkins School of Medicine Coordinator of this site? Confirm its status | Baltimore | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.